direct
base
inclus
exclus
criteria
articl
includ
final
review
compris
vitro
studi
studi
util
anim
model
studi
human
one
studi
includ
vitro
anim
model
promis
therapeut
agent
horizon
combin
lopinavirritonavir
show
excel
result
common
marmoset
current
random
control
trial
ribavirin
interferon
wide
use
combin
experi
come
number
observ
studi
although
data
heterogen
combin
might
potenti
benefit
deserv
investig
random
clinic
trial
recommend
specif
therapi
treatment
merscov
infect
one
studi
plan
random
pend
complet
studi
base
combin
lopinavirritonavir
fulli
human
polyclon
igg
antibodi
safe
well
toler
healthi
individu
agent
may
deserv
test
efficaci
conclus
despit
multipl
studi
human
consensu
optim
therapi
merscov
random
clinic
trial
need
potenti
therapi
evalu
clinic
trial
order
enhanc
therapeut
aroma
merscov
infect
repurpos
old
drug
merscov
interest
strategi
deserv
consider
use
clinic
set
middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
sinc
diseas
attract
increas
intern
interest
resolv
issu
relat
epidemiolog
clinic
featur
therapi
interest
enhanc
fact
merscov
infect
result
case
countri
around
world
june
case
link
middl
east
far
three
pattern
transmiss
merscov
viru
mainli
sporad
case
intrafamili
transmiss
healthcareassoci
transmiss
diseas
carri
high
case
fatal
rate
far
proven
effect
therapi
approv
therapi
merscov
infect
intern
nation
societi
therapeut
agent
report
literatur
base
retrospect
analysi
studi
review
avail
literatur
current
therapeut
option
diseas
includ
vitro
anim
studi
studi
human
middl
east
respiratori
syndrom
coronaviru
mer
viru
mer
virus
merscov
novel
coronaviru
drug
effect
drug
therapi
combin
drug
therapi
drug
ther
combin
drug
ther
addit
review
refer
retriev
articl
order
identifi
addit
studi
report
retriev
initi
search
includ
studi
arrang
vitro
studi
anim
studi
human
studi
includ
studi
conduct
vitro
anim
human
measur
impact
drug
therapi
merscov
exclud
studi
examin
impact
drug
therapi
coronavirus
merscov
studi
focus
drug
synthesi
extract
review
articl
studi
supplement
therapi
articl
focus
mechan
action
medic
initi
search
identifi
articl
articl
medlin
articl
embas
articl
scienc
direct
studi
exclud
review
studi
n
drug
synthesi
extract
n
supplement
therapi
n
drug
therapi
coronaviru
gener
n
site
action
differ
drug
modal
n
base
inclus
exclus
criteria
articl
includ
final
review
studi
conduct
vitro
studi
done
anim
model
studi
done
human
one
studi
includ
vitro
anim
model
fig
mani
vitro
studi
evalu
variou
agent
merscov
interferon
inf
ribavirin
hiv
proteas
inhibitor
nelfinavir
ritonavir
lopinavir
summar
tabl
vitro
studi
show
lower
inhibitori
concentr
ic
merscov
compar
addit
superior
antimerscov
activ
magnitud
higher
compar
ifnunivers
type
respect
pegyl
inhibit
effect
merscov
dose
ngml
complet
inhibit
cytopath
effect
cpe
dose
ngml
merscov
infect
vero
cell
ribavirin
nucleosid
analog
requir
activ
host
kinas
nucleotid
requir
high
vitro
dose
inhibit
merscov
replic
dose
high
achiev
vivo
combin
interferonalfa
ribavirin
vero
cell
result
reduct
dose
reduct
ribavirin
dose
hiv
proteas
inhibitor
nelfinavir
lopinavir
thought
inhibit
merscov
base
result
sar
nelfinavir
mesyl
hydrat
lopinavir
show
suboptim
effect
concentr
ec
initi
cpe
inhibit
assay
evalu
anoth
studi
mean
ec
lopinavir
use
vero
cell
merscov
requir
fusion
host
cell
replic
thu
merscov
fusion
inhibitor
camostat
heptad
repeat
peptid
evalu
vitro
camostat
inhibit
viral
entri
human
bronchial
submucos
glandderiv
cell
immatur
lung
tissu
shown
inhibit
merscov
replic
spike
proteinmedi
cellcel
fusion
camostat
effect
reduc
viral
entri
cell
infect
merscov
nitazoxanid
broadspectrum
antivir
agent
teicoplanin
inhibitor
cathepsin
l
late
endosomelysosom
cycl
blocker
entri
merscov
show
inhibitori
effect
merscov
vitro
abil
recombin
receptorbind
domain
rbdfd
inhibit
merscov
studi
express
infect
cell
inhibit
dose
id
rbdfd
compar
inhibitori
activ
untreat
cell
even
highest
dose
cyclosporin
affect
function
mani
cyclophilin
act
chaperon
facilit
protein
fold
vitro
cyclosporin
inhibit
merscov
replic
three
day
post
infect
cytopath
effect
cpe
merscov
inhibit
cyclosporin
vero
cell
mockinfect
cell
toremifen
chlorpromazin
chloroquin
evalu
use
vero
cell
human
monocytederiv
macrophag
mdm
immatur
dendrit
cell
mddc
drug
transfer
cell
h
prior
infect
merscov
h
viral
replic
inhibit
toremifen
effect
concentr
mdm
dose
low
calcul
chlorpromazin
inhibit
merscov
vero
cell
cytotox
mdm
cell
high
cytotox
concentr
cc
chloroquin
show
antivir
activ
mdm
toremifen
reduc
viru
dose
chlorpromazin
reduc
merscov
narrow
therapeut
window
high
toxic
chloroquin
chloropromazin
loperamid
test
cell
cell
treat
prior
infect
antivir
activ
chloroquin
dosedepend
chlorpomazin
show
activ
merscov
loperamid
antidiarrh
drug
inhibit
merscov
induc
cpe
two
kinas
signal
pathway
inhibitor
imatinib
mesyl
dasatinib
activ
merscov
vitro
vero
cell
imatinib
dose
depend
kill
saracatinib
broadspectrum
antivir
activ
differ
strain
merscov
h
infect
cell
saracatinib
exhibit
wherea
gemcitabin
shown
effect
merscov
infect
cell
complet
viral
deplet
dose
inhibitori
effect
resveratrol
merscov
test
use
infect
vero
cell
h
cell
death
significantli
reduc
treatment
group
resveratrol
studi
show
resveratrol
inhibit
merscov
entri
cell
resveratrol
ad
time
merscov
differ
cell
prolifer
viral
titer
compar
cell
treat
infect
antivir
activ
prodrug
remdesivir
test
merscov
infect
human
airway
epitheli
cell
hae
mean
mean
reduct
viral
titer
drug
ad
h
post
infect
util
hae
cell
infect
merscov
signific
reduct
viral
replic
dsrna
level
cell
treat
compound
novel
peptid
show
vitro
activ
merscov
infect
reduct
concentr
higher
two
neurotransmitt
antagonist
chlorpromazin
hydrochlorid
triflupromazin
hydrochlorid
inhibit
merscov
infect
vero
cell
dna
synthesi
repair
inhibitor
gemcitabin
hydrochlorid
estrogen
receptor
antagonist
toremifen
citrat
antivir
activ
merscov
estrogen
receptor
antagonist
toremifen
citrat
activ
merscov
addit
merscov
inactiv
amotosalen
ultraviolet
light
fresh
frozen
plasma
monoclon
antibodi
merscov
test
anim
model
merscov
infect
tabl
monoclon
antibodi
compar
treatment
rhesu
monkey
model
antibodi
administ
prophylaxi
oneday
prior
anim
inocul
show
signific
reduct
lung
diseas
radiograph
howev
signific
differ
compar
term
lung
patholog
p
interferon
conjunct
ribavirin
test
rhesu
macaqu
model
merscov
infect
anim
randomli
assign
either
treatment
control
group
therapi
start
h
postinfect
necropsi
show
normal
appear
lung
treatment
group
compar
control
group
viru
replic
significantli
reduc
lung
treat
anim
serum
interferon
alfa
time
level
untreat
group
day
addit
treat
group
show
reduc
system
local
level
proinflammatori
marker
monocyt
chemotact
receptor
antagonist
interferongamma
anoth
studi
conduct
util
healthi
common
marmoset
inocul
merscov
assign
four
group
control
group
mycophenol
mofetil
intraperiton
h
inocul
lopinavir
ritonavir
h
inocul
subcutan
post
inocul
lopinavirritonavir
treat
group
better
clinic
score
less
weight
reduct
less
pulmonari
infiltr
lower
viral
load
untreat
group
mycophenol
group
higher
viral
load
sever
diseas
compar
control
group
fatal
rate
higher
untreat
mycophenol
treat
group
lopinavirritonavir
treat
b
treat
group
h
inocul
human
dipeptyl
receptor
cell
bind
entri
merscov
transgen
mous
model
util
test
effect
human
mab
model
singl
dose
protect
transgen
mous
merscov
infect
control
mice
die
ten
day
postinfect
human
antibodi
mab
mousederiv
neutral
spike
receptorbind
domain
merscov
mersrbd
human
singl
intraven
dose
inject
one
day
pre
post
merscov
inocul
show
significantli
decreas
viral
titer
lung
mous
model
p
anoth
studi
done
adenovirus
express
mous
lung
mice
util
intranas
peptid
deriv
heptad
repeat
hr
domain
subunit
known
analogu
anim
either
given
intranas
h
infect
control
group
treatment
treat
group
show
decreas
viral
titer
compar
control
group
combin
interferon
show
reduct
infect
humanfcfus
version
neutral
nanobodi
test
use
transgen
mice
model
merscov
infect
mice
inject
singl
dose
trastuzumab
control
group
lethal
dose
mesrcov
treatment
group
surviv
rate
compar
surviv
rate
control
group
impact
transchromosom
tc
bovin
fulli
human
polyclon
immunoglobulin
g
igg
antibodi
test
mice
five
day
transduct
h
inocul
merscov
anim
receiv
either
intraperiton
control
tc
higg
group
viral
load
lower
mice
treat
day
postinfect
recombin
trimer
receptorbind
protein
rbdfd
test
transgen
mice
infect
merscov
anim
receiv
rbdfd
subcutan
boost
week
week
month
rbdfd
induc
igg
antibodi
merscov
maintain
least
month
surviv
rate
rbdfd
immun
mice
summari
use
differ
therapeut
agent
human
shown
tabl
first
use
antivir
agent
treat
merscov
infect
observ
patient
saudi
arabia
patient
receiv
ribavirin
oral
subcutan
interferon
unfortun
patient
die
month
due
respiratori
multiorgan
failur
four
patient
experienc
advers
drug
reaction
thrombocytopenia
anemia
pancreat
two
patient
merscov
infect
kuwait
treat
pegyl
interferon
subcutan
oral
ribavirin
one
patient
discharg
home
day
start
antivir
therapi
ribavirin
stop
one
week
therapi
due
anemia
second
patient
recov
merscov
subsequ
die
two
month
later
multidrugresist
organ
larg
retrospect
cohort
studi
includ
adult
patient
patient
patient
control
group
receiv
antivir
treatment
patient
receiv
subcutan
pegyl
interferon
oral
ribavirin
per
previous
develop
protocol
surviv
rate
day
date
diagnosi
statist
higher
treatment
group
compar
control
group
versu
p
howev
surviv
rate
differ
two
group
day
versu
p
retrospect
cohort
studi
conduct
confirm
mer
case
jeddah
saudi
arabia
start
day
one
merscov
confirm
patient
receiv
interferon
subcutan
per
week
patient
receiv
interferon
subcutan
three
time
weekli
group
also
receiv
ribavirin
oral
case
fatal
rate
versu
p
fatal
rate
patient
use
inf
posit
merscov
rtpcr
versu
neg
merscov
rtpcr
test
pegyl
ribavirin
given
two
confirm
case
riyadh
one
patient
treat
ribavirin
start
improv
day
complet
recoveri
day
second
case
confirm
case
start
medic
prophylaxi
fourth
day
patient
start
improv
discharg
home
two
week
combin
therapi
also
use
case
report
tabl
larg
cohort
studi
patient
variou
combin
interferon
ribavirin
use
differ
outcom
tabl
anoth
small
studi
util
ribavirin
interferonalfa
three
patient
receiv
therapi
within
day
admiss
compar
three
patient
receiv
therapi
day
admiss
first
group
surviv
latter
group
die
use
interferon
beta
interferon
alpha
ribavirin
associ
surviv
rate
respect
oral
lopinavir
ritonavir
use
treatment
year
old
korean
male
confirm
merscov
infect
medic
start
fourth
day
admiss
patient
achiev
full
recoveri
nine
day
treatment
one
patient
treat
pegyl
interferon
ribavirin
lopinavirritonavir
viremia
detect
two
day
follow
therapi
tripl
therapi
case
seri
eight
patient
receiv
mycophenol
mofetil
surviv
phase
random
placebocontrol
studi
util
fulli
human
polyclon
igg
antibodi
evalu
safeti
toler
agent
adult
compar
adult
receiv
placebo
trial
regist
clinicaltrialsgov
number
well
toler
report
advers
event
headach
elev
creatinin
kinas
albuminuria
sinc
emerg
merscov
infect
larg
interest
develop
effect
therapi
diseas
review
summar
avail
literatur
possibl
therapeut
option
includ
vitro
anim
human
studi
vitro
studi
show
superior
compar
ifnunivers
type
excel
cpe
inhibit
moreov
combin
ribavirin
vero
cell
show
augment
action
facilit
reduct
dose
ribavirin
lower
concentr
suggest
possibl
util
clinic
use
saracatinib
gemcitabin
differ
cytotox
compar
saracatinib
alon
less
cytotox
compar
gemcitabin
alon
mani
drug
use
vitro
show
effect
howev
translat
find
studi
clinic
trial
remain
particular
import
especi
take
consider
avail
pharmacokinet
properti
pharmacodynam
characterist
possibl
side
effect
avaialbl
clincial
experi
regard
therapi
merscov
reli
limit
case
report
observ
caseseri
wide
use
combin
ribavirin
ifn
experi
come
limit
case
report
number
observ
studi
studi
nonhomogen
natur
thu
common
conclus
could
obtain
make
firm
recommend
use
combin
routin
clinic
practic
outsid
prospect
clinic
studi
combin
lopinavirritonavir
use
common
marmoset
use
two
patient
good
outcom
combin
consid
random
control
trial
saudi
arabia
enrol
studi
began
novemb
result
avail
yet
studi
regist
juli
clinicaltrialsgov
id
current
ongo
clinic
therapeut
trial
merscov
therapi
conclus
despit
multipl
studi
human
consensu
optim
therapi
merscov
random
clinic
trial
need
potenti
therapi
evalu
clinic
trial
thu
therapi
use
conjunct
clinic
trial
interest
strategi
repurpos
old
drug
merscov
deserv
consider
use
clinic
set
none
none
